Resources Archive - Page 18 of 48

In Vivo Pharmacology Services for Ophthalmic Drug Development

Introduction The number of people with vision impairment has increased due to the continuously expanding and aging population, as well...

Radionuclide Drug Conjugates

Radiopharmaceuticals have proven to be effective agents since they can be successfully applied for both diagnostics and therapy. Radionuclide drug...

One Stop Target-to-Hit Platform: SOS1

The Son of Sevenless (SOS) protein is a guanine nucleotide exchange factor that acts as a key activator for KRAS...

One Stop Target-to-Hit Platform: RAS Family

The RAS family of small GTPases are among the most frequently mutated oncogenes in human cancer. Previously viewed as undruggable,...

One Stop Target-to-Hit Platform: CRBN-DDB1

Cereblon (CRBN) forms an E3 ligase complex together with DDB1, CUL4, and RBX1. CRBN functions as a substrate receptor of...

One Stop Target-to-Hit Platform: p53

TP53 is the most frequently mutated tumor suppressor gene in human cancer. Mutant p53 proteins not only lose wild-type p53-dependent tumor...

CRBN Structural Biology Services

Targeted protein degradation of disease-causing proteins by the E3 ligase cereblon (CRBN) represents a new therapeutic strategy for addressing challenging-to-treat...

WRN Helicase: Structural Biology Services

Inhibition of the Werner syndrome RecQ helicase (WRN) is a promising approach for the treatment of cancers commonly associated with...

mRNA-Encoded Modulators Suppress Tumor Growth

Unlike conventional protein-targeted therapies, nucleic acid therapeutics have the potential for long-lasting effects and greater target specificity. WuXi AppTec provides...

Knowledge Library